When it comes to starting social enterprises, Paul Tracey and Neil Stott would love "to see a thousand flowers bloom". But doing good for society isn’t as straightforward as it sounds and even the best ideas can fail. Their research aims to understand the elements that are needed to help social ventures thrive.
A microscopic ‘pen’ that is able to write structures small enough to trap and harness light using a commercially available printing technique could be used for sensing, biotechnology, lasers, and studying the interaction between light and matter.
Nanobots that patrol our bodies, killer immune cells hunting and destroying cancer cells, biological scissors that cut out defective genes: these are just some of technologies that Cambridge researchers are developing which are set to revolutionise medicine in the future.
Dr Tim Minshall has been appointed as the inaugural Dr John C Taylor Professor of Innovation at the University of Cambridge, a new post that will build on the University’s strengths in science, engineering and entrepreneurship. Dr Minshall, who is currently Reader in Technology & Innovation Management in the Department of Engineering and Fellow of Churchill College, will take up his new post on 1 October.
A new diagnostic test developed from research at the Universities of Cambridge and Dundee has been launched with the aim of helping eliminate the disease known as African sleeping sickness.
In this piece for The Conversation, Carlos López-Gómez from Cambridge's Institute for Manufacturing, discusses the role that small and medium-sized businesses might play in a post-Brexit economy.
Tony Kouzarides is passionate about ecosystems: well-balanced communities that flourish on mutual and dynamic interactions. But the ecosystems that excite him are not made up of plants, animals and environments. They’re made up of experts.
Nanotechnology is creating new opportunities for fighting disease – from delivering drugs in smart packaging to nanobots powered by the world’s tiniest engines.
The stirrings of a revolution are starting to ripple through hundreds of laboratories. It’s a revolution that aims to result in new medicines – faster and with fewer failures – and it’s being led by three UK universities and three global pharmaceutical companies.